2025 EAU Congress highlights: trends in minimally invasive, remote, and precision urology

doi:10.3877/cma.j.issn.1674-3253.2025.06.002

Abstract

Abstract:

This article reviews the major academic highlights of the 2025 European Association of Urology (EAU) Congress, focusing on innovations in perioperative management, the restructuring of benign prostatic hyperplasia (BPH) treatment pathways, and the application of precision biomarkers in urological oncology. The congress demostrated a systemic transition of urology from being 'surgery-centered’ to 'continuum of care-centered’, with digital health and telemonitoring, minimally invasive interventions, and liquid biopsy technologies as key driving forces. This review summarizes the academic findings, clinical implications, and policy insights from EAU Congress, aiming to provide valuable references for the advancement of urology in China.

Key words: European Association of Urology, Perioperative management, Minimally invasive therapy, Biomarkers, Precision medicine, Telemedicine

Bisheng Cheng, Peng Wu. 2025 EAU Congress highlights: trends in minimally invasive, remote, and precision urology[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(06): 693-699.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.06.002

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I06/693

References 21

[1]	Dixon S, Hill H, Flight L, et al. Cost-effectiveness of robot-assisted radical cystectomy vs open radical cystectomy for patients with bladder cancer[J]. JAMA Netw Open, 2023, 6(6): e2317255. DOI: 10.1001/jamanetworkopen.2023.17255.
[2]	Psutka SP. Prehabilitation: a multidimensional adjunct to comprehensive personalized oncologic care. But, can we make it pragmatic?[J]. Eur Urol Focus, 2024, 10(1): 1-3. DOI: 10.1016/j.euf.2024.02.001.
[3]	Briggs LG, Parke SC, Beck KL, et al. Prehabilitative/rehabilitative exercise, nutrition, and psychological support for bladder cancer: a scoping review of randomized clinical trials[J]. Cancer, 2025, 131(1): e35608. DOI: 10.1002/cncr.35608.
[4]	Checcucci E, Veccia A, Puliatti S, et al. Metaverse in surgery—origins and future potential[J]. Nat Rev Urol, 2024: 1-14. DOI: 10.1038/s41585-024-00941-4.
[5]	Geissler ME, Bereuter JP, Geissler RB, et al. Comparison of distance versus in-person laparoscopy training using a low-cost laparoscopy simulator-a randomized controlled multi-center trial[J]. Surg Endosc, 2024, 38(11): 6527-6540. DOI: 10.1007/s00464-024-11069-2.
[6]	Elterman D, Kaplan SA. Reimagining male lower urinary tract symptoms due to benign prostatic hyperplasia treatment: a new approach to first-line interventional therapy[J]. Eur Urol Focus, 2025: S2405-4569(24)00267-0. DOI: 10.1016/j.euf.2024.12.008.
[7]	Nguyen AV, Moustafa M, Nguyen DD, et al. Absence of race/ethnicity reporting in clinical trials of true minimally invasive surgical therapies for the treatment of benign prostatic hyperplasia[J]. Urology, 2025, 196: 300-308. DOI: 10.1016/j.urology.2024.09.043.
[8]	Lama J, Winograd J, Codelia-Anjum A, et al. Recent advancements in prostate catheters and stents for management of benign prostatic hyperplasia[J]. Curr Urol Rep, 2024, 26(1): 9. DOI: 10.1007/s11934-024-01235-3.
[9]	Hamouda A, Ibrahim A, Corsi N, et al. Use of the Schelin Catheter for transurethral intraprostatic anesthesia prior to Rezūm treatment[J]. Can J Urol, 2024, 31(1): 11802-11808.
[10]	Raizenne BL, Zheng X, Oumedjbeur K, et al. Prostatic artery embolization compared to transurethral resection of the prostate and prostatic urethral lift: a real-world population-based study[J]. World J Urol, 2023, 41(1): 179-188. DOI: 10.1007/s00345-022-04218-6.
[11]	Kaplan SA, Moss JL, Freedman SJ. Two-year long-term follow-up of treatment with the Optilume BPH catheter system in a randomized controlled trial for benign prostatic hyperplasia (The PINNACLE Study)[J]. Prostate Cancer Prostatic Dis, 2024, 27(3): 531-536. DOI: 10.1038/s41391-024-00833-z.
[12]	Rojanasarot S, Cutone B, Durand K, et al. Patients' perspectives on attributes while choosing minimally invasive surgery for benign prostatic hyperplasia procedures: experience from men undergoing water vapor thermal therapy[J]. J Endourol, 2023, 37(5): 575-580. DOI: 10.1089/end.2022.0607.
[13]	Bouhadana D, Nguyen DD, Schwarcz J, et al. Development of a patient decision aid for the surgical management of lower urinary tract symptoms secondary to benign prostatic hyperplasia[J]. BJU Int, 2021, 127(1): 131-135. DOI: 10.1111/bju.15307.
[14]	Gatto F, Dabestani S, Bratulic S, et al. Plasma and urine free glycosaminoglycans as monitoring biomarkers in nonmetastatic renal cell carcinoma-a prospective cohort study[J]. Eur Urol Open Sci, 2022, 42: 30-39. DOI: 10.1016/j.euros.2022.06.003.
[15]	Gatto F, Bratulic S, Jonasch E, et al. Plasma and urine free glycosaminoglycans as monitoring and predictive biomarkers in metastatic renal cell carcinoma: a prospective cohort study[J]. JCO Precis Oncol, 2023, 7: e2200361. DOI: 10.1200/PO.22.00361.
[16]	Ben-David R, Lidagoster S, Geduldig J, et al. Undetectable pre-radical cystectomy circulating tumour DNA status predicts improved oncological outcomes[J]. BJU Int, 2025, 135(3): 473-480. DOI: 10.1111/bju.16556.
[17]	Ben-David R, Lidagoster S, Geduldig J, et al. The prognostic significance of circulating tumor DNA in patients with positive lymph node disease after robotic-assisted radical cystectomy: a contemporary analysis[J]. Urol Oncol Semin Orig Investig, 2025, 43(1): 66.e9-66.e17. DOI: 10.1016/j.urolonc.2024.08.006.
[18]	D’Andrea VD, Magnani CJ, Ernandez J, et al. Impact of DNA repair deficiency in the evolving treatment landscape of bladder cancer[J]. Curr Urol Rep, 2024, 26(1): 12. DOI: 10.1007/s11934-024-01242-4.
[19]	Steel N, Bauer-Staeb CMM, Ford JA, et al. Changing life expectancy in European countries 1990–2021: a subanalysis of causes and risk factors from the global burden of disease study 2021[J]. Lancet Public Health, 2025, 10(3): e172-e188. DOI: 10.1016/S2468-2667(25)00009-X.
[20]	Hawkes RE, Marsden AM, Cotterill S, et al. Exposure to behaviour change techniques and self-management tasks in a nationally-implemented digital intervention for type 2 diabetes self-management: Analysis of usage data[J]. Soc Sci Med, 2025, 370: 117858. DOI: 10.1016/j.socscimed.2025.117858.
[21]	D’Andrea D, Mostafid H, Gontero P, et al. Unmet need in non-muscle-invasive bladder cancer failing Bacillus calmette-guérin therapy: a systematic review and cost-effectiveness analyses from the international bladder cancer group[J]. Eur Urol Oncol, 2025, 8(1): 216-229. DOI: 10.1016/j.euo.2024.10.012.

Please choose a citation manager

Content to export